	CLINICAL INVESTIGATION REPORT			
	Department	Rep. Nr	Date	Rev.
	Clinical Research	01	11-Dec-23	1.0

Study Title	An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision acetabular cup.
Short Title	DELTA REVISION CUP
Protocol ID	H-34
Product	CE marked DELTA Revision acetabular cup
Study Phase	Enrollment
Subject Population	49
Sponsor	Limacorporate Spa Via Nazionale 52, 33030, Villanova di San Daniele (UD), Italy
Sponsor representative	Federica Azzimonti Clinical Research Manager, Limacorporate S.p.A.
Principal Investigator	Dr. Jerzy Bialecki Samodzielny Publiczny Szpital Kliniczny im. Prof. Adama Grucy CMKP in Otwock, Poland
Sub-Investigator(s)	Dr. Julia Macias Dr. Pawel Bartosz Samodzielny Publiczny Szpital Kliniczny im. Prof. Adama Grucy CMKP in Otwock, Poland
Statistical Analysis	Intermediate statistical analysis: Limacorporate S.p.A.

Clinical investigation identified as H-34 and entitled “An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision acetabular cup” has been conducted in accordance with ISO 14155:2020 “Clinical investigation of medical devices for human subjects — Good Clinical Practice” and with the ethical principles of the Declaration of Helsinki.

Table of contents

List of Abbreviations	3
List of Tables	4
List of Figures	4
1.0 SUMMARY	5
2.0 INTRODUCTION	7
3.0 RESULTS	8
3.1 Study Flowchart	8
3.2 Patient population and preoperative data	9
3.3 Intraoperative data	11
3.3.1 Surgery data	11
3.3.2 Implant information	12
3.4 Efficacy analysis	13
3.4.1 Clinical results	13
3.4.2 Radiographic results	14
3.5 Safety analysis	18
3.5.1 Adverse events reporting	18
3.5.2 Device deficiency	20
3.5.3 Device survivorship	20
4.0 SUMMARY AND OUTLOOK	20

List of Abbreviations

ADE	Adverse Device Effect
AE	Adverse Event
BMI	Body-Mass Index
eCRF	electronic Case Report Form
FU	Follow-Up
HHS	Harris Hip Score
ISO	International Organization for Standardization
OHS	Oxford Hip Score
ROM	Range of Motion
SADE	Serious Adverse Device Effect
SAE	Serious Adverse Event
SD	Standard Deviation
THA	Total Hip Arthroplasty
UHMWPE	Ultra High Molecular Weight Polyethylene
USADE	Unexpected Serious Adverse Device Effect

List of Tables

Table 1 Demographics of study population.....	9
Table 2 Gender, working status, activity level, smoking and drinking habits, concomitant medications of study population.....	9
Table 3 Preoperative assessment of study population.	10
Table 4 Surgical data of study population with regard to surgical approach, anesthesia, intraoperative complications and prophylaxis therapy.....	11
Table 5 Surgery data of study population in terms of surgery time and hematocrit (intraoperative and postoperative).	11
Table 6 bone stock quality and bone grafting on the acetabular side of study population	11
Table 7 Bone stock quality and bone grafting on the femoral side of study population	12
Table 8 Implant details of the acetabular side of study population.....	12
Table 9 Implant details of the femoral head of study population.....	13
Table 10 Implant used on the femoral side of study population.	13
Table 11 Change in HHS from preoperative (baseline) to 2-year follow-up	13
Table 12 Change in total score description of HHS from preoperative (baseline) to 2-year follow-up.....	14
Table 13 Change in OHS from preoperative (baseline) to 2-year follow-up.	14
Table 14 Change in total score description of OHS from preoperative (baseline) to 2-year follow-up.....	14
Table 15 Preoperative radiographic assessment	15
Table 16 Postoperative assessment of acetabular radiographic migration.....	15
Table 17 Postoperative assessment of radiolucent lines on the acetabular cup.....	16
Table 18 Postoperative assessment of osteolysis on the acetabular cup.....	16
Table 19 Postoperative radiographic assessment (presence of distant femoral component migration/subsidence, presence of periprosthetic fractures, dislocation, loosening, bone remodeling cortical hypertrophy/stress shielding).	17
Table 20 Postoperative radiographic assessment (heterotopic ossification, infection, presence of hardware failure, cysts, osteophytes, sclerosis/calcifications).....	18
Table 21 Adverse events occurred (seriousness, severity, causal relationship with study medical device and study procedure, outcome of the event).	18
Table 22 Detailed description of adverse events occurred.....	19

List of Figures

Figure 1 Study flowchart.....	8
-------------------------------	---

1.0 SUMMARY

Name of sponsor/Company	Limacorporate S.p.A
Study ID	H-34
Study title	An open label, observational, prospective, longitudinal cohort study to evaluate safety, clinical and radiographic outcomes of total hip arthroplasty with DELTA Revision acetabular cup.
Name of study product	CE marked DELTA Revision acetabular cup
Investigators & study site(s)	Dr. Jerzy Bialecki Samodzielny Publiczny Szpital Kliniczny im. Prof. Adama Grucy CMKP in Otwock, Poland
Publication (reference)	N/A
Study period:	Date of first enrolment: 14/09/2021 Date of last enrolment: N/A Current phase: enrollment
Objectives:	Primary objective - To assess the clinical outcomes of the DELTA Revision acetabular cup used in real life settings over a period of 2 years Secondary objectives - To assess the radiographical and clinical outcomes of the DELTA Revision acetabular cup used in real life settings over a period of 2 years -To evaluate the safety profile of the DELTA Revision acetabular cup used in real life settings over a period of 5 years - To describe baseline data (demographic data, primary diagnosis, aetiology, affected side, type of surgery and intra-operative data) of patients with Delta Revision acetabular cup
Criteria for evaluation/Endpoints:	Primary endpoint: - The evaluation of Harris Hip Score (HHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant. Secondary endpoints: - Evaluation of Range of Motion (ROM) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year and 2 years after the implant;

	<ul style="list-style-type: none"> - Evaluation of Oxford Hip Score (OHS) at pre-operative visit, intraoperatively/discharge, 2 months, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years after the implant; - Survivorship of the implant (Kaplan-Meier estimate) at 2 years of follow-up after surgery; - Radiographic implant evaluation and stability assessment of the DELTA Revision acetabular cup at the following timepoints: at discharge, 2 months, 6 months, 1 year, and 2 years after the implant - Incidence, type and severity of all the Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Device Effects (ADEs) and Serious Adverse Device Effects (SADEs) at intraoperatively, discharge, 2 months, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years after the implant.
Number of patients:	Planned sample size: 49 Enrolled: 21 Completed: 0
Inclusion and exclusion criteria:	<p>Inclusion criteria: Patients must meet the following criteria for study entry:</p> <ol style="list-style-type: none"> 1. Male or female. 2. Age \geq 18 years old. 3. All patients must give written informed consent approved by the study site's Institutional Review Board (IRB)/Ethical Committee (EC). 4. Adult patients in whom a decision has already been made to perform a total hip arthroplasty with DELTA Revision acetabular cup as per indication for use. The decision to implant DELTA Revision acetabular cup must be taken prior to, and independently from the decision to enroll the patient. This decision should be made in accordance with routine clinical practice at the study site concerned. 5. Patient is able to comply with the protocol <p>Exclusion criteria: A patient will not be included in the study if they meet any of the following criteria:</p> <ol style="list-style-type: none"> 1. Adult patients with any DELTA Revision acetabular cup contraindication for use as reported in the current local Instruction for use. 2. For female patients, current pregnancy and/or lactation or planning a pregnancy.
Statistical methods:	An internal statistical analysis was performed on all collected data, using Microsoft® Excel.
Date of the report:	11 December 2023

2.0 INTRODUCTION

H-34 is a post-marketing, prospective, observational, monocentric, longitudinal cohort clinical study that aims at collecting clinical, patient-reported and radiographic early outcomes after total hip arthroplasty (THA) with DELTA Revision acetabular cup. The study is being carried out at the Samodzielny Publiczny Szpital Kliniczny im. Prof. Adama Grucy CMKP in Otwock, Poland. Data are being collected prospectively and following hospital standard of care. Every patient is followed from preoperative visit up to 5 years after surgery.

Study population consist of 49 patients in need for a hip revision surgery and deemed suitable for receiving a DELTA Revision acetabular cup. The expected enrollment period is 30 months. So far, 23 patients have been screened and 21 patients have been enrolled, of which 5 performed the 2-year follow-up visit.

Study visits are performed according to the local standard of care. Timelines and temporal windows are the following:

- Pre-operative visit
- Intraoperative visit
- Discharge visit
- Follow-Up 2 months: ± 30 days
- Follow-Up 6 months: ± 60 days
- Follow-Up 12 months: ± 6 months
- Follow-Up 24 months: ± 6 months
- Survival Follow-Up visit at 3,4 and 5 years: ± 6 months

Relevant data will be captured on an eCRF. These data will be transmitted to the sponsor for analysis, will be anonymous and will be identified by a patient number. As this study is non-interventional, all data collected will be in accordance with the practice of clinicians implanting DELTA Revision acetabular cup.

At pre-operative, intra-operative, discharge and each follow-up visit, the following information will be collected:

- Medical history and demographic data (only at pre-operative visit);
- Primary diagnosis and physical examination (only at pre-operative visit);
- Surgical data (only at intra-operative visit);
- X-rays as per standard care;
- Radiographic evaluation;
- Clinical assessment (HHS, ROM, OHS);
- Assessment of type, nature and severity of any DD, AE, ADE, SAE and SADE;
- Survivorship of implant.

The study is still in the enrollment phase and this intermediate clinical study report is based on eCRF data extraction performed on the 11th of December 2023.

3.0 RESULTS

3.1 Study Flowchart




Figure 1 Study flowchart

3.2 Patient population and preoperative data

Variable	N	Mean	SD	Min	Max	Median
Pt enrolled	21					
Weight (kg)	21	78	14	57	110	79
Height (cm)	21	168	10	152	189	167
BMI (kg/m ²)	21	28	4	22	35	27.3
Age (years)	21	64	13	40	87	68

Table 1 Demographics of study population.

Variable	n	%
Gender	21	
Female	12	57
Male	9	43
Race	21	
White	21	100
Working status	21	
Retired	10	48
Not Working	8	38
Active	2	10
Missing data	1	5
Activity level	21	
Sedentary	17	81
Normal	3	14
Intense	0	0
Missing Data	1	5
Smoking habits	21	
No smoking	16	76
Smoking, daily	5	24
Alcohol drinking	21	
No alcohol	20	95
Alcohol drinking, occasionally	1	
Alcohol drinking, daily		
Concomitant medication	21	
Yes	15	71
No	5	
-	1	

Table 2 Gender, working status, activity level, smoking and drinking habits, concomitant medications of study population.

Variable	n	%
Affected side	21	
Left	11	52.4
Right	10	47.6
Primary diagnosis	21	
Presence of bone stock of poor quality or inadequate for other reconstructive techniques as indicated by deficiencies of the acetabulum	10	47.6
Revision of previous unsuccessful femoral head replacement, cup arthroplasty or other procedure	9	42.9
Clinical management problem where arthrodesis or alternative reconstruction techniques are less likely to achieve satisfactory results	2	9.5
Previous hip surgeries on the affected side	21	
Yes	21	100
No	0	0
Previous hip treatments or surgeries on the contralateral side	21	
Yes	8	38.1
No	13	61.9
Description of pain	21	
No pain	3	14.3
Unable to describe	0	0
At rest	4	19
Occasional start-up pain	4	19
Always start-up pain	6	28.6
With every movement	3	14.3
-	1	4.8
Pain therapy	21	
None	7	33.3
NSAIDs, occasionally	3	14.3
NSAIDs, regularly	4	19
Steroids, occasionally	0	0
Steroids, regularly	0	0
Opiates, occasionally	3	14.3
Opiates, regularly	4	19
Osteoporosis	21	
Yes	0	0
No	20	95.2
-	1	4.8

Table 3 Preoperative assessment of study population.

3.3 Intraoperative data

3.3.1 Surgery data

Variable	n	%
Surgical approach	21	
Postero-lateral	21	100
Anesthesia	21	
Subarachnoid	19	90.5
General	2	9.5
Intraoperative complications	21	
No	19	90.5
Yes, not implant-related	2	9.5
Antibiotic prophylaxis	21	
Yes	21	100
No	0	0
Antithrombotic prophylaxis	21	
Yes	21	100
No	0	0
Antihemorrhagic prophylaxis	21	
Yes	12	57.1
No	8	38.1

Table 4 Surgical data of study population with regard to surgical approach, anesthesia, intraoperative complications and prophylaxis therapy.

Variable	n	Mean	SD	Min	Max	Median
Surgery time	21	158	37	105	235	155
Intraoperative hematocrit	21	41	4	32	50	41
Immediate postoperative hematocrit	21	31	5	23	39	31

Table 5 Surgery data of study population in terms of surgery time and hematocrit (intraoperative and postoperative).

Variable	n	%
Bone stock quality - acetabulum	21	
Normal	2	9.5
Porotic	17	81
Sclerotic	2	9.5
Bone grafting	21	
Yes	16	76.2
No	5	23.8
Graft material	21	
Allograft chips	8	38.1
Autograft	1	4.8
Other	8	38.1
-	4	19

Table 6 bone stock quality and bone grafting on the acetabular side of study population.

Variable	n	%
Bone stock quality - femur	21	
Normal	10	47.6
Porotic	10	47.6
Sclerotic	1	4.8
Bone grafting	21	
Yes	1	4.8
No	20	95.2
Graft material	21	
-	20	95.2
Other	1	4.8

Table 7 Bone stock quality and bone grafting on the femoral side of study population.

3.3.2 Implant information

Variable	n	%	Variable	n	%
Cup type	21		Cup liner material	21	
DELTA-REVISION	14	66.7	Neutral UHMWPE X-LIMA + Ti6Al4V	2	9.5
DELTA-REVISION+TT	5	23.8	Neutral UHMWPE X-LIMA + Ti6Al4V w/ angled 10° spacer	1	4.8
HEMISPHERIC MODULE ECC. 12	1	4.8	Neutral UHMWPE X-LIMA + Ti6Al4V w/ angled 20° spacer	1	4.8
DELTA-REVISION+TT	1	4.8	Protruded UHMWPE X-LIMA + Ti6Al4V	7	33.3
HEMISPHERIC MODULE ECC. 18	1	4.8	Protruded UHMWPE X-LIMA + Ti6Al4V w/ neutral spacer	3	14.3
-	1	4.8	Protruded UHMWPE X-LIMA + Ti6Al4V w/ neutral +5 spacer	1	4.8
Cup diameter	21		Protruded UHMWPE X-LIMA + Ti6Al4V w/ angled 20° spacer	4	19
50 mm	1	4.8	-	2	9.5
54 mm	4	19	Cup liner size	21	
58 mm	6	28.6	ID 32 mm-MEDIUM	10	47.6
62 mm	5	23.8	ID 32 mm-LARGE	1	4.8
66 mm	4	19	ID 36 mm-LARGE	8	38.1
-	1	4.8	-	2	9.5
Cup cement	21				
No	21				

Table 8 Implant details of the acetabular side of study population.

Variable	n	%
Head type	21	
Modular	19	90.5
-	2	9.5
Head material	21	
BioloX (r) Delta	15	71.4
BioloX (r) Delta + Ti6Al4V	1	4.8
CoCrMo Taper 12/14	2	9.5
CoCrMo Taper 14/16	1	4.8
-	2	9.5
Head diameter	21	100
32 mm	11	52.4
36 mm	8	38.1
-	2	9.5
Head size	21	
S	6	28.6
M	4	19
L	7	33.3
XL	2	9.5
-	2	9.5

Table 9 Implant details of the femoral head of study population.

Variable	n	%
Stem type	21	
H-MAX S standard	2	9.5
Modulus-R	2	9.5
Modulus Taper B	3	14.3
Revision	4	19
Competitor (no Lima)	10	47.6

Table 10 Implant used on the femoral side of study population.

3.4 Efficacy analysis

3.4.1 Clinical results

3.4.1.1 Clinical results – Harris Hip Score (HHS)

Time point	n	Mean	SD	Min	Max	Median
Preoperative	21	38.6	15.7	12	64	41
2 months FU	17	60.6	12.7	42	80	56
6 months FU	14	73.9	15.5	45	94	74.5
1 year FU	9	84.3	12.7	65	97	89
2 years FU	5	77	13.8	57	93	79

Table 11 Change in HHS from preoperative (baseline) to 2-year follow-up

	Preoperative		2 months FU		6 months FU		1 year FU		2 years FU	
Total score description	n	%	n	%	n	%	n	%	n	%
Very poor	20	95.2	9	52,9	3	21.4	0	0	1	20
Poor	1	4.8	1	5,9	1	7.1	2	22.2	0	0
Fair	0	0	6	35,3	5	35.7	1	11.1	2	40
Good	0	0	1	5,9	1	7.1	2	22.2	1	20
Excellent	0	0	0	0,0	4	28,6.	4	44.4	1	20

Table 12 Change in total score description of HHS from preoperative (baseline) to 2-year follow-up.

3.4.1.2 Clinical results – Oxford Hip Score (OHS)

Time point	n	Mean	SD	Min	Max	Median
Preoperative	21	19.7	8.9	3	37	21
2 months FU	17	30.9	7.6	17	43	33
6 months FU	14	38.6	5.8	28	47	38.5
1 year FU	9	41.2	6.3	28	48	42
2 years FU	5	39.4	8.5	25	46	42

Table 13 Change in OHS from preoperative (baseline) to 2-year follow-up.

	Preoperative		2 months FU		6 months FU		1 year FU		2 years FU	
Total score description	n	%	n	%	n	%	n	%	n	%
Very poor	0	0	0	0	0	0	0	0.	0	0
Poor	17	81	7	41.2	0	0	0	0.	1	20
Fair	2	9.5	2	11.8	3	2.4	1	11.1	0	0
Good	2	9.5	6	35.3	6	42.9	2	22.2	1	20
Excellent	0	0	2	11.8	5	35.7	6	66.7	3	60

Table 14 Change in total score description of OHS from preoperative (baseline) to 2-year follow-up.

3.4.2 Radiographic results

3.4.2.1 Preoperative radiographic evaluation

Variable	n	%
Varus/valgus deformity	21	
Neutral	19	90.5
Varus	2	9.5
Valgus	0	0
Osteoarthritis severity	21	
Grade I	11	52.4
Grade II	2	9.5
Grade III	0	0
Grade IV	4	19
-	4	19
Presence of osteophytes	21	
Yes	1	4.8
No	17	81
Missing Data	3	14.3

Presence of cysts	21	
Yes	1	4.8
No	17	81
Missing Data	3	14.3
Sclerosis	21	
None	15	71.4
Slight	4	19
Moderate	2	9.5

Table 15 Preoperative radiographic assessment

3.4.2.2 Postoperative radiographic evaluation

	Immediate postoperative		2 months FU		6 months FU		12 months FU		24 months FU	
Variable	n	%	n	%	n	%	n	%	n	%
Acetabular component migration	20		17		14		9		5	
Absent	19	95	17	100	14	100	9	100	5	100
Present	1	5	0	0	0	0	0	0	0	0

Table 16 Postoperative assessment of acetabular radiographic migration

		Zone 1		Zone 2		Zone 3	
Immediate postoperative	Radiolucent lines	n	%	n	%	n	%
	None	16	80	15	75	19	95
	<1 mm	0	0	0	0	0	0
	≥1 to <2 mm	0	0	2	10	0	0
	≥ 2 to < 3 mm	0	0	0	0	0	0
	≥3 to <4 mm	0	0	1	5	0	0
	≥ 4 mm	4	20	2	10	1	5
2 months FU	Radiolucent lines	n	%	n	%	n	%
	None	11	65	14	82	16	94
	<1 mm	0	0	0	0	1	6
	≥1 to <2 mm	0	0	2	12	0	0
	≥ 2 to < 3 mm	0	0	0	0	0	0
	≥3 to <4 mm	2	12	0	0	0	0
	≥ 4 mm	4	24	1	6	0	0
6 months FU	Radiolucent lines	n	%	n	%	n	%
	None	14	100	9	64	13	93
	<1 mm	0	0	0	0	0	0
	≥1 to <2 mm	0	0	3	21	0	0
	≥2 to <3 mm	0	0	1	7	1	7
	≥3 to <4 mm	0	0	0	0	0	0
	≥ 4 mm	0	0	1	7	0	0
1 year FU	Radiolucent lines	n	%	n	%	n	%
	None	8	89	7	78	9	100
	<1 mm	0	0	0	0	0	0

2 years FU	≥1 to <2 mm	1	11	1	11	0	0
	≥2 to <3 mm	0	0	0	0	0	0
	≥3 to <4 mm	0	0	0	0	0	0
	≥ 4 mm	0	0	1	11	0	0
	Radiolucent lines	n	%	n	%	n	%
	None	5	100	4	80	4	80
	<1 mm	0	0	0	0	0	0
	≥1 to <2 mm	0	0	0	0	1	20
	≥2 to <3 mm	0	0	1	20	0	0
	≥3 to <4 mm	0	0	0	0	0	0
	≥ 4 mm	0	0	0	0	0	0

Table 17 Postoperative assessment of radiolucent lines on the acetabular cup

		Zone 1		Zone 2		Zone 3	
Immediate postoperative	Osteolysis acetabular component	n	%	n	%	n	%
	None	18	90	18	90	19	95
2 months FU	1 mm	0	0	0	0	0	0
	2 mm	0	0	1	5	0	0
	> 2mm	2	10	1	5	0	0
	Osteolysis acetabular component	n	%	n	%	n	%
6 months FU	None	13	76	16	94	17	100
	1 mm	0	0	0	0	0	0
	2 mm	0	0	0	0	0	0
	> 2mm	4	24	1	6	0	0
1 year FU	Osteolysis acetabular component	n	%	n	%	n	%
	None	13	93	11	79	13	93
	1 mm	0	0	0	0	0	0
	2 mm	1	7	2	14	0	0
2 years FU	> 2mm	0	0	1	7	1	7
	Osteolysis acetabular component	n	%	n	%	n	%
	None	8	89	8	89	9	100
	1 mm	1	11	1	11	0	0
	2 mm	0	0	0	0	0	0
	> 2mm	0	0	0	0	0	0
	Osteolysis acetabular component	n	%	n	%	n	%
	None	5	100	5	100	5	100
	1 mm	0	0	0	0	0	0
	2 mm	0	0	0	0	0	0
	> 2mm	0	0	0	0	0	0

Table 18 Postoperative assessment of osteolysis on the acetabular cup

	Immediate postoperative		2 months FU		6 months FU		1 year FU		2 years FU	
Variable	n	%	n	%	n	%	n	%	n	%
Presence of Distal Femoral Component Migration/Subsidence	20		17		14		9		5	
Absent (<5 mm)	20	100	17	100	14	100	9	100	5	100
Present (>5 mm)	0	0	0	0	0	0	0	0	0	0
Presence of any Periprosthetic Fracture	20		17		14		9		5	
Absent	17	85	17	100	14	100	9	100	5	100
Present	3	15	0	0	0	0	0	0	0	0
Type of periprosthetic fracture	3		-		-		-		-	
Type A	2	66,7								
Type B1	1	33,3								
Dislocation	20		17		14		9		5	
Absent	20	100	17	100	14	100	9	100	5	100
Loosening	20		17		14		9		5	
Absent	20	100	17	100	14	100	9	100	5	100
Bone remodellingCortical Hypertrophy	20		17		14		9		5	
Absent	20	100	17	100	13	92.9	9	100	5	100
Present	0	0	0	0	1*	7.1	0	0	0	0
Bone remodelingStress Shielding	20		17		13		9		5	
Absent	20	100	17	100	13	100	9	100	5	100
Present	0	0	0	0	0	0	0	0	0	0

*New bone appear in the zone 2 of acetabulum

Table 19 Postoperative radiographic assessment (presence of distant femoral component migration/subsidence, presence of periprosthetic fractures, dislocation, loosening, bone remodeling cortical hypertrophy/stress shielding).

	Immediate postoperative		2 months FU		6 months FU		1 year FU		2 years FU	
Variable	n	%	n	%	n	%	n	%	n	%
Heterotopic Ossification	20		17		14		9		5	
Grade 0	18	90	12	70.6	9	64.3	6	66.7	2	40
Grade 1	2	10	5	29.4	5	35.7	2	22.2	2	40
Grade 2	0	0	0	0	0	0	1	11.1	1	20
Infection	20		17		14		9		5	
Absent	20	100	17	100	14	100	9	100	5	100
Presence of Hardware Failure	20		17		14		9		5	
Absent	20	100	0	0	14	100	9	100	5	100
Presence of cysts	20		17		14		9		5	
Absent	20	100	17	100	14	100	9	100	5	100
Presence of osteophytes	20		16		14		9		5	
Absent	20	100	16	100	14	100	9	100	5	100

Presence of Sclerosis Calcifications	20		17		14		9		5	
Absent	20	100	17	100	13	92.9	9	100	5	100
Present	0	0	0	0	1	7.1	0	0	0	0

Table 20 Postoperative radiographic assessment (heterotopic ossification, infection, presence of hardware failure, cysts, osteophytes, sclerosis/calcifications).

3.5 Safety analysis

3.5.1 Adverse events reporting

Adverse events	n	%	Seriousness type	n	%
Total adverse events	8		Death	0	0
Serious	6	75	Life-threatening	0	0
			Hospitalization or prolongation of hospitalization	4	66.7
			Permanent impairment	0	0
			Medical or surgical intervention required to prevent any of the above	2	33.3
Not serious	2	25			
Severity	n	%	Outcome of the event	n	%
Mild	1	12.5	Recovered	5	62.5
Moderate	4	50	Ongoing	3	37.5
Severe	3	37.5			
Causality: relationship to study medical device	n	%	Causality: relationship to study procedure	n	%
Not Related	7	87.5	Not Related	5	62.5
Possible	0	0	Possible	1	12.5
Probable	1	12.5	Probable	1	12.5
Causal relationship (related)	0	0	Causal relationship (related)	1	12.5

Table 21 Adverse events occurred (seriousness, severity, causal relationship with study medical device and study procedure, outcome of the event).

Pt ID	Adverse Event (diagnosis, if known, or signs/ symptoms)	Event narrative	Detail all possible and suspected causes including relevant medical history	Current clinical status	Severity	Causality: relationship to study medical device	Causality: relationship to study procedure	Expectedness	Action taken	Detailed treatment	Was the device permanently removed?	Outcome of the event	Is the patient still in the study?
101 - 1	Surgery of the contralateral side.	Total hip replacement of right hip.			Moderate	Not Related	Not Related	N/A	None		No	Recovered	Yes
101 - 5	Intraoperative fracture of femur shaft	The femur shaft was weakened because of previous use of metal loop;	The femur shaft was weakened because of previous use of metal loop; 25 years ago THA of both hips, 2011- revision of right hip Ecofit;	On the first control visit 22 Nov 2021 patient is walking with 2 crutches;	Severe	Not Related	Not Related	N/A	Other intraoperative reduction and fixation of the fracture		No	Recovered	Yes
101 - 9	Cup loosening	Early postoperative cup loosening,	Probable cause is technical mistake at first operation with Delta Revision implantation. Too proximal cup implantation and not sufficient cup hook stabilization at the ischial bone. Second cause could be wrong position of stable stem, various position in femur.	Patient undergone revision surgery at 2021-12-03, with cup and stem reimplantation.	Severe	Not Related	Not Related	N/A	Not pharmacological	Revision surgery with cup and stem removal. Reimplantation Trident Multihole cup with augment and Restoration stem.	Yes	Recovered	Withdrawn
101 - 10	Dyspnoea, fluid collection in lungs	Chronic heart failure exacerbation	Chronic heart failure	Good	Moderate	Not Related	Not Related	N/A	Pharmacological	Pharmacological treatment: Furosemid 40mg 2xday from 14.01.2022 to 18.01.2022. With this treatment we got an improvement.	No	Recovered	Yes
101 - 13	Intraoperative fracture of great trochanter	During the reduction of endoprostheses intraoperatively, it came to fracture of great trochanter. Without displacement. It was fixed with two Dall- Miles loops.	-	Rehabilitation.	Mild	Not Related	Probable	Anticipated	Not pharmacological	Fracture was fixed with two Dall- Miles loops.	No	Recovered	Yes
101 - 14	Dislocation of left hip	at night, when standing up of bed she felt pain	Suspected cause is initial migration of the cup.	Reoperation is planned.	Severe	Not Related	Possible	Anticipated	Not pharmacological	13.06.2022- reposition of the hip;	No	Ongoing	Withdrawn
101 - 17	Periprosthetic fracture- fracture of right pubis bone	A stress fracture was diagnosed, with possible loosening of the endoprosthesis of the operated hip.	There is a possibility that the connection of screws with the acetabulum is stiff enough to cause a fracture of the pubis bone.	Under the observation.	Moderate	Probable	Causal relationship (related)	Unanticipated	Not pharmacological	Diagnostics of periprosthetic fracture- computed tomography	No	Ongoing	Yes
101 - 24	Intraoperatively, when rotating the femur fracture of greater trochanter was observed	Femur was weakened after removal of Proxima stem.		The fracture was intraoperatively reduced and fixated with 120mm Synthes plate.	Moderate	Not Related	Not Related	N/A	Other intraoperatively fixation of fracture		No	Ongoing	Yes

Table 22 Detailed description of adverse events occurred.

3.5.2 Device deficiency

No device deficiencies were recorded so far.

3.5.3 Device survivorship

As described in Table 22 of the Adverse Events sections, two subjects underwent revision surgery of Delta Revision cup and were thus withdrawn from the study. The serious adverse events that led to a revision surgery occurred to patient 101-9 and 101-14, 2 weeks and 6 weeks after surgery, respectively.

4.0 SUMMARY AND OUTLOOK

Preliminary results suggest that the treatment with Delta Revision cup results in an improvement of clinical outcomes from preoperative to 2 year-follow-up. This can be observed both for HHS and OHS. No relevant radiographic issues have been identified from the radiographic analysis. Only 2 cases of revision have been recorded so far.